Skip to content
OpenCapital
Get started

BridgeBio Pharma BBIO Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$110.6MBeat by $2.4MDiluted EPS-$0.95Miss by $0.12
Revenue estimate$108.1M
EPS estimate-$0.83

Next report

Aug 4, 2026 (In 3 weeks)
Revenue estimate$220.2M
EPS estimate-$0.64

Financials

Q2 2025

Income statement

See full
Revenue$110.6M+5,000%
Gross profit$106.9M+6,710%
Operating income-$134.3M+23.5%
Net income-$183.8M-143%
EPS (diluted)-$0.95-144%

Balance sheet

See full
Cash & equivalents$749.0M+83.6%
Total debt$8.8M-98.0%
Total equity-$1.8B-63.6%
Total assets$1.1B+36.0%

Cash flow

See full
Operating cash flow-$80.7M—
CapEx$594.0K+1,000%
Free cash flow-$81.3M—

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$8.44B+78.1%
Enterprise value$7.7B+61.1%
P/S35.8×+14.2×

Profitability

See full
Gross margin96.2%-2.7pp
Operating margin-278.4%+67.6pp
Net margin-332.9%+461pp
FCF margin-278.4%—

Returns & leverage

See full
Current ratio5.2×+0.6×

Versus estimates

Revenue

Q1 2026$194.5MBeat by $16.4MQ4 2025$154.2MBeat by $7.3MQ3 2025$120.7MMiss by $27.5M
Q2 2025$110.6MBeat by $2.4M
Q1 2025$116.6MBeat by $48.2MQ4 2024$5.9MBeat by $1.8M

Diluted EPS

Q1 2026-$0.84Miss by $0.14Q4 2025-$1.00Miss by $0.29Q3 2025-$0.95Miss by $0.07
Q2 2025-$0.95Miss by $0.12
Q1 2025-$0.88Beat by $0.12Q4 2024-$1.31Miss by $0.22

Ask the moment BridgeBio Pharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did BridgeBio Pharma report Q2 2025 earnings?
BridgeBio Pharma (BBIO) reported Q2 2025 earnings on August 5, 2025 after market close.
What were BridgeBio Pharma's Q2 2025 revenue and EPS?
BridgeBio Pharma reported revenue of $110.6M and diluted EPS of $-0.95 for Q2 2025.
Did BridgeBio Pharma beat estimates in Q2 2025?
Revenue beat the consensus estimate of $108.1M by $2.4M. EPS missed the consensus estimate of $-0.83 by $0.12.
How did BridgeBio Pharma's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4999.9% from $2.2M a year earlier and diluted EPS grew 6.9% from $-1.02.
Where can I find BridgeBio Pharma's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-103192) directly on SEC EDGAR. The filing index links above go to sec.gov.